Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.

Sharon D, Cathelin S, Mirali S, Di Trani JM, Yanofsky DJ, Keon KA, Rubinstein JL, Schimmer AD, Ketela T, Chan SM.

Sci Transl Med. 2019 Oct 30;11(516). pii: eaax2863. doi: 10.1126/scitranslmed.aax2863.

PMID:
31666400
2.

Global Interactome Mapping of Mitochondrial Intermembrane Space Proteases Identifies a Novel Function for HTRA2.

Botham A, Coyaud E, Nirmalanandhan VS, Gronda M, Hurren R, Maclean N, St-Germain J, Mirali S, Laurent E, Raught B, Schimmer A.

Proteomics. 2019 Oct 16:e1900139. doi: 10.1002/pmic.201900139. [Epub ahead of print]

PMID:
31617661
3.

Tafazzin modulates cellular phospholipid composition to regulate AML stemness.

Seneviratne AK, Xu M, Schimmer AD.

Mol Cell Oncol. 2019 Jun 11;6(5):e1620051. doi: 10.1080/23723556.2019.1620051. eCollection 2019.

PMID:
31528696
4.

Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.

Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, Bratman SV, Schuh AC, Chan SM.

Blood Adv. 2019 Aug 13;3(15):2307-2311. doi: 10.1182/bloodadvances.2019000306. No abstract available.

5.

Phospholipid metabolism regulates AML growth and stemness.

Xu M, Seneviratne AK, Schimmer AD.

Aging (Albany NY). 2019 Jun 25;11(12):3895-3897. doi: 10.18632/aging.102055. No abstract available.

6.

De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX.

Tan J, Grouleff JJ, Jitkova Y, Diaz DB, Griffith EC, Shao W, Bogdanchikova AF, Poda G, Schimmer AD, Lee RE, Yudin AK.

J Med Chem. 2019 Jul 11;62(13):6377-6390. doi: 10.1021/acs.jmedchem.9b00878. Epub 2019 Jun 26.

PMID:
31187989
7.

The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids.

Seneviratne AK, Xu M, Aristizabal Henao JJ, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD.

Cell Stem Cell. 2019 Jun 6;24(6):1007. doi: 10.1016/j.stem.2019.04.020. No abstract available.

PMID:
31173706
8.

17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells.

Dai S, Yang S, Hu X, Sun W, Tawa G, Zhu W, Schimmer AD, He C, Fang B, Zhu H, Zheng W.

Mol Cancer Ther. 2019 Jul;18(7):1265-1277. doi: 10.1158/1535-7163.MCT-18-1241. Epub 2019 May 15.

PMID:
31092562
9.

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M.

Cancer Cell. 2019 May 13;35(5):721-737.e9. doi: 10.1016/j.ccell.2019.03.014. Epub 2019 May 2.

PMID:
31056398
10.

Emotion And Symptom-focused Engagement (EASE): a randomized phase II trial of an integrated psychological and palliative care intervention for patients with acute leukemia.

Rodin G, Malfitano C, Rydall A, Schimmer A, Marmar CM, Mah K, Lo C, Nissim R, Zimmermann C.

Support Care Cancer. 2019 Apr 17. doi: 10.1007/s00520-019-04723-2. [Epub ahead of print]

PMID:
31001692
11.

The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.

Seneviratne AK, Xu M, Henao JJA, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD.

Cell Stem Cell. 2019 Apr 4;24(4):621-636.e16. doi: 10.1016/j.stem.2019.02.020. Epub 2019 Mar 28. Erratum in: Cell Stem Cell. 2019 Jun 6;24(6):1007.

PMID:
30930145
12.

Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity.

Hu D, Sun X, Liao X, Zhang X, Zarabi S, Schimmer A, Hong Y, Ford C, Luo Y, Qi X.

Acta Neuropathol. 2019 Jun;137(6):939-960. doi: 10.1007/s00401-019-01993-2. Epub 2019 Mar 15.

13.

Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review.

Calvillo-Argüelles O, Jaiswal S, Shlush LI, Moslehi JJ, Schimmer A, Barac A, Thavendiranathan P.

JAMA Cardiol. 2019 Apr 1;4(4):380-387. doi: 10.1001/jamacardio.2019.0302.

PMID:
30865214
14.

The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.

Yehudai D, Liyanage SU, Hurren R, Rizoska B, Albertella M, Gronda M, Jeyaraju DV, Wang X, Barghout SH, MacLean N, Siriwardena TP, Jitkova Y, Targett-Adams P, Schimmer AD.

Haematologica. 2019 May;104(5):963-972. doi: 10.3324/haematol.2018.195172. Epub 2018 Dec 20.

15.

Pain in patients with newly diagnosed or relapsed acute leukemia.

Shaulov A, Rodin G, Popovic G, Caraiscos VB, Le LW, Rydall A, Schimmer AD, Zimmermann C.

Support Care Cancer. 2019 Aug;27(8):2789-2797. doi: 10.1007/s00520-018-4583-5. Epub 2018 Dec 8.

PMID:
30535882
16.

MTCH2-mediated mitochondrial fusion drives exit from naïve pluripotency in embryonic stem cells.

Bahat A, Goldman A, Zaltsman Y, Khan DH, Halperin C, Amzallag E, Krupalnik V, Mullokandov M, Silberman A, Erez A, Schimmer AD, Hanna JH, Gross A.

Nat Commun. 2018 Dec 3;9(1):5132. doi: 10.1038/s41467-018-07519-w.

17.

Metabolic Flexibility in Leukemia-Adapt or Die.

Nachmias B, Schimmer AD.

Cancer Cell. 2018 Nov 12;34(5):695-696. doi: 10.1016/j.ccell.2018.10.012.

18.

Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.

Khoury H, He R, Schimmer A, Beadle JR, Hostetler KY, Minden MD.

Chemotherapy. 2018;63(4):225-237. doi: 10.1159/000491705. Epub 2018 Oct 29.

PMID:
30372692
19.

The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AML.

Barghout SH, Schimmer AD.

Oncotarget. 2018 Sep 28;9(76):34198-34199. doi: 10.18632/oncotarget.26153. eCollection 2018 Sep 28. No abstract available.

20.

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.

Brandwein JM, Seki JT, Atenafu EG, Rostom A, Lutynski A, Rydlewski A, Schimmer AD, Schuh AC, Gupta V, Yee KWL.

Support Care Cancer. 2019 Jun;27(6):2295-2300. doi: 10.1007/s00520-018-4515-4. Epub 2018 Oct 19.

PMID:
30341536
21.

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.

McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469.

22.

The experience of medical communication in adults with acute leukemia: Impact of age and attachment security.

Fraser B, Korenblum C, Mah K, Watt S, Malfitano C, Rydall A, Schimmer A, Zimmermann C, Rodin G.

Psychooncology. 2019 Jan;28(1):122-130. doi: 10.1002/pon.4919. Epub 2018 Nov 12.

PMID:
30312520
23.

Acyldepsipeptide Analogs Dysregulate Human Mitochondrial ClpP Protease Activity and Cause Apoptotic Cell Death.

Wong KS, Mabanglo MF, Seraphim TV, Mollica A, Mao YQ, Rizzolo K, Leung E, Moutaoufik MT, Hoell L, Phanse S, Goodreid J, Barbosa LRS, Ramos CHI, Babu M, Mennella V, Batey RA, Schimmer AD, Houry WA.

Cell Chem Biol. 2018 Aug 16;25(8):1017-1030.e9. doi: 10.1016/j.chembiol.2018.05.014. Epub 2018 Jun 28.

24.

Mitochondrial Shapeshifting Impacts AML Stemness and Differentiation.

Schimmer AD.

Cell Stem Cell. 2018 Jul 5;23(1):3-4. doi: 10.1016/j.stem.2018.05.026.

25.

Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.

Barghout SH, Patel PS, Wang X, Xu GW, Kavanagh S, Halgas O, Zarabi SF, Gronda M, Hurren R, Jeyaraju DV, MacLean N, Brennan S, Hyer ML, Berger A, Traore T, Milhollen M, Smith AC, Minden MD, Pai EF, Hakem R, Schimmer AD.

Leukemia. 2019 Jan;33(1):37-51. doi: 10.1038/s41375-018-0167-0. Epub 2018 Jun 8.

PMID:
29884901
26.

Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience.

Alduaij W, McNamara CJ, Schuh A, Arruda A, Sukhai M, Kanwar N, Thomas M, Spiegel J, Kennedy JA, Stockley T, Tsui H, Devlin R, Sibai H, Maze D, Schimmer A, Yee K, Chan S, Kamel-Reid S, Gupta V.

Hemasphere. 2018 May 4;2(3):e44. doi: 10.1097/HS9.0000000000000044. eCollection 2018 Jun.

27.

Prevalence of oral lesions in and dental needs of patients with newly diagnosed acute leukemia.

Watson E, Wood RE, Maxymiw WG, Schimmer AD.

J Am Dent Assoc. 2018 Jun;149(6):470-480. doi: 10.1016/j.adaj.2018.01.019. Epub 2018 Mar 30.

PMID:
29606275
28.

AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.

Kavanagh S, Heath E, Hurren R, Gronda M, Barghout SH, Liyanage SU, Siriwardena TP, Claudio J, Zhang T, Sukhai M, Stockley TL, Kamel-Reid S, Rostom A, Lutynski A, Khalaf D, Rydlewski A, Chan SM, Gupta V, Maze D, Sibai H, Schuh AC, Yee K, Minden MD, Schimmer AD.

Leuk Res. 2018 May;68:22-28. doi: 10.1016/j.leukres.2018.02.012. Epub 2018 Feb 20.

PMID:
29518628
29.

The importance of meaningful activity in people living with acute myeloid leukemia.

Deckert AL, Gheihman G, Nissim R, Chung C, Schimmer AD, Zimmermann C, Rodin G.

Leuk Res. 2018 Apr;67:86-91. doi: 10.1016/j.leukres.2018.02.009. Epub 2018 Feb 15.

PMID:
29482172
30.

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.

Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, Sukhai M, Thomas M, Bartoszko J, Ho J, Siddiq N, Maze D, Schimmer A, Schuh A, Sibai H, Yee K, Claudio J, Devlin R, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2017 Sep 8;1(20):1729-1738. doi: 10.1182/bloodadvances.2017009530. eCollection 2017 Sep 12.

31.

Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study.

So M, Mamdani MM, Morris AM, Lau TTY, Broady R, Deotare U, Grant J, Kim D, Schimmer AD, Schuh AC, Shajari S, Steinberg M, Bell CM, Husain S.

Clin Microbiol Infect. 2018 Aug;24(8):882-888. doi: 10.1016/j.cmi.2017.11.009. Epub 2017 Nov 11.

32.

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients.

Bhimji A, Bhaskaran A, Singer LG, Kumar D, Humar A, Pavan R, Lipton J, Kuruvilla J, Schuh A, Yee K, Minden MD, Schimmer A, Rotstein C, Keshavjee S, Mazzulli T, Husain S.

Clin Microbiol Infect. 2018 Jun;24(6):640-645. doi: 10.1016/j.cmi.2017.09.018. Epub 2017 Sep 29.

33.

Emerging therapies for acute myeloid leukemia: translating biology into the clinic.

Kavanagh S, Murphy T, Law A, Yehudai D, Ho JM, Chan S, Schimmer AD.

JCI Insight. 2017 Sep 21;2(18). pii: 95679. doi: 10.1172/jci.insight.95679. eCollection 2017 Sep 21. Review.

34.

Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification.

Chen Y, Pourabdollah M, Atenafu EG, Tierens A, Schimmer A, Chang H.

Leuk Res. 2017 Oct;61:39-43. doi: 10.1016/j.leukres.2017.08.011. Epub 2017 Aug 25.

PMID:
28886412
35.

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.

Bartoszko J, Panzarella T, McNamara CJ, Lau A, Schimmer AD, Schuh AC, Sibai H, Maze D, Yee KWL, Devlin R, Gupta V.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):774-781. doi: 10.1016/j.clml.2017.06.031. Epub 2017 Jun 29.

PMID:
28711573
36.

Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells.

Schimmer AD.

Cancer Discov. 2017 Jul;7(7):670-672. doi: 10.1158/2159-8290.CD-17-0476.

37.

Traumatic stress in patients with acute leukemia: A prospective cohort study.

Rodin G, Deckert A, Tong E, Le LW, Rydall A, Schimmer A, Marmar CR, Lo C, Zimmermann C.

Psychooncology. 2018 Feb;27(2):515-523. doi: 10.1002/pon.4488. Epub 2017 Aug 10.

PMID:
28665521
38.

Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes.

Hershenfeld SA, Maki K, Rothfels L, Murray CS, Nixon S, Schimmer AD, Doherty MC.

Leuk Res. 2017 Aug;59:93-96. doi: 10.1016/j.leukres.2017.05.023. Epub 2017 Jun 1.

PMID:
28599190
39.

Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.

Farshchi Zarabi S, Chan S, Gupta V, Khalaf D, Lutynski A, Minden MD, Rostom A, Rydlewski A, Schuh AC, Sibai H, Yee KWL, Schimmer AD.

Leuk Lymphoma. 2018 Jan;59(1):237-240. doi: 10.1080/10428194.2017.1323273. Epub 2017 Jun 9. No abstract available.

PMID:
28595467
40.

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B-Cell Acute Lymphoblastic Leukemia.

Khoral P, Atenafu EG, Craddock KJ, Schimmer A, Chang H.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):215-219. doi: 10.1016/j.clml.2017.02.009. Epub 2017 Feb 17.

PMID:
28395813
41.

Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.

Guo RJ, Atenafu EG, Schimmer AD, Minden MD, Chang H.

Int J Lab Hematol. 2017 Aug;39(4):429-437. doi: 10.1111/ijlh.12649. Epub 2017 Mar 20.

PMID:
28318150
42.

Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.

Liyanage SU, Hurren R, Voisin V, Bridon G, Wang X, Xu C, MacLean N, Siriwardena TP, Gronda M, Yehudai D, Sriskanthadevan S, Avizonis D, Shamas-Din A, Minden MD, Bader GD, Laposa R, Schimmer AD.

Blood. 2017 May 11;129(19):2657-2666. doi: 10.1182/blood-2016-10-741207. Epub 2017 Mar 10.

43.

Biological and clinical consequences of NPM1 mutations in AML.

Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD.

Leukemia. 2017 Apr;31(4):798-807. doi: 10.1038/leu.2017.30. Epub 2017 Jan 23. Review.

PMID:
28111462
44.

Synchronous T lymphoblastic lymphoma and myeloid neoplasm with PDGFRA rearrangement.

Pourabdollah M, Gupta M, Schimmer A, Chang H.

Int J Lab Hematol. 2017 Feb;39(1):e28-e32. doi: 10.1111/ijlh.12596. Epub 2016 Dec 25. No abstract available.

PMID:
28013529
45.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
46.

Characterizing the mitochondrial DNA polymerase gamma interactome by BioID identifies Ruvbl2 localizes to the mitochondria.

Liyanage SU, Coyaud E, Laurent EM, Hurren R, Maclean N, Wood SR, Kazak L, Shamas-Din A, Holt I, Raught B, Schimmer A.

Mitochondrion. 2017 Jan;32:31-35. doi: 10.1016/j.mito.2016.11.001. Epub 2016 Nov 11.

PMID:
27845271
47.

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.

Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE, Baran N, Haferlach T, Su X, Flores ER, Gonzalez D, Konoplev S, Samudio I, DiNardo C, Majeti R, Schimmer AD, Li W, Wang T, Tiziani S, Konopleva M.

Oncotarget. 2016 Nov 29;7(48):79722-79735. doi: 10.18632/oncotarget.12944.

48.

Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.

Rotin LE, MacLean N, Aman A, Gronda M, Lin FH, Hurren R, Wang X, Wrana JL, Datti A, Al-Awar R, Minden MD, Schimmer AD.

Haematologica. 2016 Nov;101(11):e449-e453. Epub 2016 Sep 1. No abstract available.

49.

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.

Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y, Gronda M, Hurren R, Shamas-Din A, Schuh AC, Schimmer AD.

Cancer Med. 2016 Nov;5(11):3031-3040. doi: 10.1002/cam4.845. Epub 2016 Oct 13.

50.

Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.

Deotare U, Shaheen M, Brandwein JM, Pitcher B, Kamel-Reid S, Yee KWL, Schimmer A, Minden MD, Gupta V, Schuh AC.

Hematol Oncol. 2017 Dec;35(4):810-813. doi: 10.1002/hon.2341. Epub 2016 Sep 6.

PMID:
27597292

Supplemental Content

Loading ...
Support Center